Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jun;24(6):429-434.
doi: 10.5005/jp-journals-10071-23415.

Cytokine Storm in Novel Coronavirus Disease (COVID-19): Expert Management Considerations

Yatin Mehta  1 , Subhal B Dixit  2 , Kapil G Zirpe  3 , Abdul S Ansari  4
Affiliations

Cytokine Storm in Novel Coronavirus Disease (COVID-19): Expert Management Considerations

Yatin Mehta et al. Indian J Crit Care Med. 2020 Jun.

Abstract

Aim/objective/introduction: Cytokine storm or cytokine release syndrome (CRS) is inevitable in severe and critically ill patients with novel coronavirus disease-2019 (COVID-19). This review aimed to discuss current therapeutic options for the management of CRS in COVID-19.

Background: Cytokine storm is caused by the colossal release of proinflammatory cytokines [e.g., IL (interleukin)-2, IL-6, IL-8 TNF (tumor necrosis factor)-α, etc.] causing dysregulated, hyperimmune response. This immunopathogenesis leads to acute lung injury and acute respiratory distress syndrome (ARDS). Targeting cytokine storm with the therapies that are already available in India with the support of published guidelines and consensus can assist in achieving a better outcome in COVID-19.

Review results: We predominantly included published guidelines or consensus recommendations about the management of cytokine storm in COVID-19. From the existing literature evidence, it is observed that among the currently available agents, low-dose corticosteroids and heparin can be beneficial in managing cytokine storm. The use of serine protease inhibitors such as ulinastatin has been advised by some experts. Though therapies such as high-dose vitamin C and interleukin-6 inhibitors (e.g., tocilizumab) have been advised, the evidence regarding their use for cytokine storm in COVID-19 is limited. Therapies such as Janus kinase inhibitors (JAK) inhibitors and Neurokinin-1 receptor (NK-1) antagonists are still in research. Besides, pharmaceutical treatments, use of blood purification strategies, and convalescent plasma may be life-saving options in some of the critically ill COVID-19 patients. For these therapies, there is a need to generate further evidence to substantiate their use in CRS management.

Conclusion: Current management of COVID-19 is preventive and supportive. Different therapies can be used to prevent and treat the cytokine storm. More research is needed for further supporting the use of these treatments in COVID-19.

How to cite this article: Mehta Y, Dixit SB, Zirpe KG, Ansari AS. Cytokine Storm in Novel Coronavirus Disease (COVID-19): Expert Management Considerations. Indian J Crit Care Med 2020;24(6):429-434.

Keywords: Acute respiratory distress syndrome; COVID-19; Coronavirus; Cytokine storm; Immunosuppressants.

PubMed Disclaimer

Conflict of interest statement

Source of support: Nil Conflict of interest: None

References

    1. https://www.who.int/emergencies/diseases/novel-coronavirus-2019. [[Accessed on 14th April 2020].]. https://www.who.int/emergencies/diseases/novel-coronavirus-2019
    1. https://www.mohfw.gov.in/ [[Accessed on 14th April 2020].]. https://www.mohfw.gov.in/
    1. World Health Organization. Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected Interim guidance 13 March 2020. https://www.who.int/docs/default-source/coronaviruse/clinical-management... https://www.who.int/docs/default-source/coronaviruse/clinical-management... Available from.
    1. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study [published correction appears in Lancet Respir Med 2020;8(4):e26]. Lancet Respir Med. 2020;;8((5):):475––481.. doi: 10.1016/S2213-2600(20)30079-5. doi: - DOI - PMC - PubMed
    1. Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol. 2017;;39((5):):529––539.. doi: 10.1007/s00281-017-0629-x. DOI: - DOI - PMC - PubMed

LinkOut - more resources